Corrections or additions?
This article by Barbara Fox was prepared for the May 8, 2002
edition of
U.S. 1 Newspaper. All rights reserved.
Geneva Expands
Apparently following a strategy to transfer many of
its operations to the East Coast of the United States, a Swiss
pharmaceutical
company, Novartis, has moved the headquarters of its generic company
from Colorado to Princeton, and next month it will complete the move
with an expansion. Novartis’ Geneva Pharmaceuticals is moving seventy
people from the Enterprise Business Center (Morgan Lane) to 506
Carnegie
Center.
“We are one of the top five generic companies in the United
States,”
says Oliver Esman, Geneva’s vice president of human resources,
“and
we manufacture a wide range of generic products.”
“It is a wonderful labor market here, not only in technical
knowledge
but in range of pharmaceutical and nonpharmaceutical people we have
been able to attract,” says Esman. “We have hired an
accounting
group and some HR people, and we brought our sales and marketing
teams.”
Based in Basel, Switzerland, Novartis has just announced it will move
its command center for global research from Basel to Cambridge,
Massachusetts,
where it will establish a center for genetic research. According to
the Wall Street Journal (May 7), the move represents “one of the
most significant defections yet from Europe’s once-might
pharmaceuticals
industry in favor of the U.S., now the world’s largest and most
lucrative
pharmaceuticals market.”
Novartis’ North American administrative headquarters is in East
Hanover.
Its generic company, Geneva, is based in Kundl, Austria, and now the
North American headquarters will be at the Carnegie Center. The R&D
center, the former Invamed facility, will remain on Route 130 in
Dayton.
Colorado will retain its manufacturing, distribution, and logistics
facilities in Broomfield, a suburb of Denver.
“The heart of the pharmaceutical industry, in terms of management,
is in north Jersey,” says Esman, “and more of our customers
are on the East Coast.” Esman grew up in Pittsburgh and graduated
from Cornell in 1974. He came to Geneva last fall from a similar
position
at another generic company, Schein Pharma in north Jersey.
Geneva’s CEO John Sedor (pronounced Seedor) joined the company last
year. He had worked in Pennsylvania for Rhone Poulenc Rorer and its
predecessors. A graduate of Pittsburgh’s Duquesne University (Class
of 1970) he has also been at Centeon in King of Prussia. His most
recent job was with Verion, an Exton, Pennsylvania startup that works
on microencapsulation technology.
A mid to late June move is planned.
Geneva Pharmaceuticals (ADR), 101 Morgan Lane,Suite 200, Plainsboro 08536. John Sedor, CEO. 609-750-4734; fax,609-750-4797.Www.genevarx.comPrevious StoryNext StoryCorrections or additions?This page is published by PrincetonInfo.com— the web site for U.S. 1 Newspaper in Princeton, New Jersey.
